Genzyme Corp-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Genzyme Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013242
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:73
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genzyme Corp (Genzyme), a subsidiary of Sanofi, is a biotechnology company that develops specialty treatments targeting rare and special unmet medical needs. Its product pipeline comprises Dupilumab for atopic dermatitis and asthma; Patisiran for familial amyloid polyneuropathy; Isatuximab for multiple myeloma; and Fitisuran for Hemophilia, among others. The company primarily focuses on rare genetic disorders, kidney diseases, orthopedics, organ transplant, cancer, and immune disease. Genzyme also develops products for the treatment of cardiovascular diseases, neurodegenerative diseases and other areas. It operates a research and development lab and manufacturing plants in the US, Belgium and Ireland. The company has presence in the Americas, Europe, Asia-Pacific, Middle East and Africa. Genzyme is headquartered in Massachusetts, the US.

Genzyme Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Genzyme Corp, Medical Devices Deals, 2011 to YTD 2017 11
Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Genzyme Corp, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Genzyme Acquires Caprelsa from AstraZeneca 15
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For US$98.5 Million 16
Venture Financing 17
Edimer Pharma Raises US$18 Million In Series B Financing 17
Ultragenyx Pharma Raises US$75 Million In Series B Financing 19
Proteostasis Therapeutics Raises US$71 Million In Series A Financing 21
Fate Therapeutics Secures Venture Financing 23
Fate Therapeutics Raises US$36 Million In Series B Financing 25
Partnerships 27
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 27
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 28
Recursion Pharma Enters into Research Agreement with Genzyme 29
Ablynx Enters into Research Agreement with Genzyme 30
Cystic Fibrosis Foundation Therapeutics Expands Research Agreement with Genzyme 31
Voyager Therapeutics Enters into Development Agreement with Genzyme 32
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 33
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 34
Genzyme Enters Into Research Agreement With Cleveland Clinic 35
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 36
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 38
Genzyme Enters Into Research Agreement With Cystic Fibrosis Foundation Therapeutics 39
ChemRar Enters Into Co-Development Agreement With Genzyme 40
Merger 41
Sanofi Japan and Genzyme Japan Merge 41
Licensing Agreements 42
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 42
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 43
Equity Offering 44
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 44
KaloBios Pharma Completes IPO For US$70 Million 46
Asset Transactions 48
Admedus Acquires Manufacturing Facility From Genzyme Australasia 48
Genzyme Completes Sale Of Pharma Intermediates Business To International Chemical Investors 49
Biovail Labs Acquires Canadian Rights To Cholestagel From Genzyme 50
Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 51
Acquisition 53
Sanofi-Aventis Completes Acquisition Of Genzyme 53
Genzyme Corp – Key Competitors 56
Genzyme Corp – Key Employees 57
Genzyme Corp – Locations And Subsidiaries 58
Head Office 58
Other Locations & Subsidiaries 58
Joint Venture 61
Recent Developments 62
Government and Public Interest 62
Dec 20, 2016: Sanofi Genzyme Announces Recipients of 2016 Patient Advocacy Leadership (PAL) Awards 62
Product News 64
11/10/2016: Genzyme Europe Receives CHMP Positive Opinion recommending change to the terms of the marketing authorisation for Caprelsa 64
10/06/2016: BARDA Awards $37.6 million Contract to Sanofi to Supply Leukine (sargramostim) for Potential Public Health Emergency 65
03/03/2016: Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease 66
Clinical Trials 68
Apr 11, 2017: Sanofi Genzyme to present data on GLD52 (GZ402668) at AAN 68
Feb 14, 2017: Sanofi Initiates Phase 2 Clinical Trial to Evaluate Therapy for Genetic Form of Parkinson’s Disease 69
Nov 17, 2016: Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease to Begin in the UK 70
Nov 04, 2016: Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease 71
Other Significant Developments 72
Mar 22, 2017: Sanofi Genzyme Extends Its Multiple Myeloma Journey Partners Program To Cities Nationwide To Help Improve Patient Outcomes Through Peer-to-Peer Education 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List of Tables
Genzyme Corp, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Genzyme Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Genzyme Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Genzyme Corp, Deals By Therapy Area, 2011 to YTD 2017 10
Genzyme Corp, Medical Devices Deals, 2011 to YTD 2017 11
Genzyme Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Genzyme Acquires Caprelsa from AstraZeneca 15
Genzyme Completes Acquisition Of Leukine Manufacturing Facility From Bayer HealthCare For US$98.5 Million 16
Edimer Pharma Raises US$18 Million In Series B Financing 17
Ultragenyx Pharma Raises US$75 Million In Series B Financing 19
Proteostasis Therapeutics Raises US$71 Million In Series A Financing 21
Fate Therapeutics Secures Venture Financing 23
Fate Therapeutics Raises US$36 Million In Series B Financing 25
Alnylam Pharma Enters into Agreement with Sanofi Genzyme 27
Sanofi Genzyme Enters into Research Agreement with Johns Hopkins School of Medicine 28
Recursion Pharma Enters into Research Agreement with Genzyme 29
Ablynx Enters into Research Agreement with Genzyme 30
Cystic Fibrosis Foundation Therapeutics Expands Research Agreement with Genzyme 31
Voyager Therapeutics Enters into Development Agreement with Genzyme 32
Genzyme Enters into Co-Development Agreement with University of Florida and University of Pennsylvania 33
Charcot-Marie-Tooth Association Enters into Agreement with Genzyme to Discover Therapies for CMT1A 34
Genzyme Enters Into Research Agreement With Cleveland Clinic 35
Alnylam Pharma And Genzyme Enter Into Agreement For RNAi Therapeutics As Genetic Medicines 36
Alnylam Pharma And Genzyme Expands Co-Development Agreement For RNAi Therapeutics 38
Genzyme Enters Into Research Agreement With Cystic Fibrosis Foundation Therapeutics 39
ChemRar Enters Into Co-Development Agreement With Genzyme 40
Sanofi Japan and Genzyme Japan Merge 41
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 42
Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 43
Alnylam Pharma Raises USD70.7 Million in Private Placement of Shares 44
KaloBios Pharma Completes IPO For US$70 Million 46
Admedus Acquires Manufacturing Facility From Genzyme Australasia 48
Genzyme Completes Sale Of Pharma Intermediates Business To International Chemical Investors 49
Biovail Labs Acquires Canadian Rights To Cholestagel From Genzyme 50
Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 51
Sanofi-Aventis Completes Acquisition Of Genzyme 53
Genzyme Corp, Key Competitors 56
Genzyme Corp, Key Employees 57
Genzyme Corp, Other Locations 58
Genzyme Corp, Subsidiaries 59
Genzyme Corp, Joint Venture 61

★海外企業調査レポート[Genzyme Corp-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Parkway Pantai Ltd:企業の戦略的SWOT分析
    Parkway Pantai Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Mangalore Refinery and Petrochemicals Ltd (MRPL):企業の財務・戦略的SWOT分析
    Mangalore Refinery and Petrochemicals Ltd (MRPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Bridgestone Corporation:企業の戦略・SWOT・財務分析
    Bridgestone Corporation - Strategy, SWOT and Corporate Finance Report Summary Bridgestone Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Gilead Sciences Inc (GILD):企業の財務・戦略的SWOT分析
    Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • National Dentex Corp:企業の戦略的SWOT分析
    National Dentex Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Implenia AG:戦略・SWOT・企業財務分析
    Implenia AG - Strategy, SWOT and Corporate Finance Report Summary Implenia AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Asahi Group Holdings Ltd:戦略・SWOT・企業財務分析
    Asahi Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Asahi Group Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Salzgitter AG:企業の戦略・SWOT・財務情報
    Salzgitter AG - Strategy, SWOT and Corporate Finance Report Summary Salzgitter AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Transdev Group SA:企業の戦略的SWOT分析
    Transdev Group SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Eli Lilly and Co (LLY):医療機器:M&Aディール及び事業提携情報
    Summary Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, immune disorders, men's health and musculoskeletal problems. It als …
  • Martin Midstream Partners LP (MMLP):企業の財務・戦略的SWOT分析
    Martin Midstream Partners LP (MMLP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Mannatech Inc (MTEX):企業の財務・戦略的SWOT分析
    Mannatech Inc (MTEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Thales SA:企業の戦略・SWOT・財務情報
    Thales SA - Strategy, SWOT and Corporate Finance Report Summary Thales SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Burgan Bank Sak:企業の戦略・SWOT・財務分析
    Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report Summary Burgan Bank Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • 88 Energy Ltd (88E):石油・ガス:M&Aディール及び事業提携情報
    Summary 88 Energy Ltd (88 Energy), formerly Tangiers Petroleum Ltd, is an exploration and production company that develops oil-rich provinces. The company offers discovery, exploration and development of onshore oil projects. It has oil and gas assets in Morocco and Australia. 88 Energy’s Morocco pr …
  • BlackBerry Ltd:戦略・SWOT・企業財務分析
    BlackBerry Ltd - Strategy, SWOT and Corporate Finance Report Summary BlackBerry Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Redx Pharma Plc (REDX):企業の財務・戦略的SWOT分析
    Summary Redx Pharma Plc (Redx Pharma), formerly Redx Pharma Ltd is a drug discovery and development company that develops early stage and small molecule therapeutics. The company’s pipeline products include inhibitors for oncology and anti-infectives for treatment of diseases that include influenza …
  • Hang Lung Properties Limited:企業の戦略・SWOT・財務情報
    Hang Lung Properties Limited - Strategy, SWOT and Corporate Finance Report Summary Hang Lung Properties Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Vermont Electric Cooperative Inc:企業の戦略的SWOT分析
    Vermont Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Pathfinder Energy Pty Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Pathfinder Energy Pty Ltd (Pathfinder) is an oil and gas company that offers exploration and development of conventional and unconventional oil and gas resources. The company acquires exploration permits and matures prospects using geophysics and geology. It maintains exploration licenses in …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆